Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction

Vaccine ◽  
2022 ◽  
Author(s):  
R. Villena ◽  
M.T. Valenzuela ◽  
M. Bastías ◽  
M.E. Santolaya
Keyword(s):  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease ◽  
Vaccine Introduction

scholarly journals Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine

2013 ◽  
Vol 66 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Wiebke Hellenbrand ◽  
Johannes Elias ◽  
Ole Wichmann ◽  
Manuel Dehnert ◽  
Matthias Frosch ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Invasive Meningococcal Disease

Invasive Meningococcal Disease in Africa’s Meningitis Belt: More Than Just Meningitis?

2019 ◽  
Vol 220 (Supplement_4) ◽  
pp. S263-S265 ◽  
Author(s):  
Heather E Reese ◽  
Olivier Ronveaux ◽  
Jason M Mwenda ◽  
Andre Bita ◽  
Adam L Cohen ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Disease Surveillance ◽  
Clinical Presentation ◽  
Case Fatality ◽  
Clinical Syndrome ◽  
Invasive Meningococcal Disease ◽  
World Health ◽  
Case Fatality Ratio ◽  
Meningitis Belt

Abstract Since the progressive introduction of the meningococcal serogroup A conjugate vaccine within Africa’s meningitis belt beginning in 2010, the burden of meningitis due to Neisseria meningitidis serogroup A (NmA) has substantially decreased. Non-A serogroups C/W/X are now the most prevalent. Surveillance within the belt has historically focused on the clinical syndrome of meningitis, the classic presentation for NmA, and may not adequately capture other presentations of invasive meningococcal disease (IMD). The clinical presentation of infection due to serogroups C/W/X includes nonmeningeal IMD, and there is a higher case-fatality ratio associated with these non-A serogroups; however, data on the nonmeningeal IMD burden within the belt are scarce. Expanding surveillance to capture all cases of IMD, in accordance with the World Health Organization’s updated vaccine-preventable disease surveillance standards and in preparation for the anticipated introduction of a multivalent meningococcal conjugate vaccine within Africa’s meningitis belt, will enhance meningococcal disease prevention across the belt.

Invasive meningococcal disease in children in Ireland, 2001–2011

2016 ◽  
Vol 101 (12) ◽  
pp. 1125-1129 ◽  
Author(s):  
Cilian Ó Maoldomhnaigh ◽  
Richard J Drew ◽  
Patrick Gavin ◽  
Mary Cafferkey ◽  
Karina M Butler
Keyword(s):  
Meningococcal Disease ◽  
Clinical Presentation ◽  
Assessment Tool ◽  
Vaccination Campaign ◽  
Invasive Meningococcal Disease ◽  
Historical Cohort ◽  
Vaccine Introduction ◽  
Group B ◽  
Study Hospital ◽  
Paediatric Intensive Care Units

BackgroundIn 1999, invasive meningococcal disease was hyperendemic in Ireland at 14.75/100 000 population, with 60% group B and 30% group C diseases. National sepsis guidelines and meningococcal C vaccines were introduced in 2000. Despite a spontaneous decline in group B infection, invasive meningococcal disease remains a leading cause of sepsis. This study characterises the epidemiology of invasive meningococcal disease in children in Ireland since the introduction of meningococcal C vaccine and reviews its clinical presentation, hospital course and outcome in anticipation of meningococcal B vaccine introduction.MethodsNational surveillance data were obtained from the Health Protection Surveillance Centre. A retrospective study of all meningococcal cases at two tertiary paediatric hospitals was conducted from 2001 to 2011. Records were reviewed using a standardised assessment tool. A study of 407 meningococcal cases published in 2002 provided comparative data.ResultsOf 1820 cases <19 years of age notified nationally, 382 (21%) cases attended a study hospital; 94% group B, 3% group C, 225 (59%) male, median age 5 years (range 0.1–18). Fever was absent at presentation in 18%. Fifteen patients (3.6%) died. 221 (61%) were admitted to paediatric intensive care units (PICU). Permanent sequelae occurred in 9.4%. Compared with the historical cohort, there were differences in presentation, an increase in PICU interventions, but no significant decline in morbidity or mortality.ConclusionsDespite the meningococcal C vaccination campaign, invasive meningococcal disease continues to cause serious morbidity and claim lives. Group B infections remain dominant. As children who die often present with fulminant disease, preventive strategies including use of meningococcal B vaccine are needed to avert death and sequelae.

scholarly journals Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy

Vaccine ◽  
2018 ◽  
Vol 36 (29) ◽  
pp. 4222-4227 ◽  
Author(s):  
Patrizio Pezzotti ◽  
Alessandro Miglietta ◽  
Arianna Neri ◽  
Cecilia Fazio ◽  
Paola Vacca ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Conjugate Vaccine ◽  
Meningococcal Disease ◽  
Vaccine Effectiveness ◽  
Invasive Meningococcal Disease
Sign in / Sign up

Export Citation Format

Share Document